Germanwings schreef op 21 oktober 2016 16:43:
Filgotinib
Filgotinib is an exciting molecule in co- development with Galapagos (NASDAQ:GLPG)for the treatment of multiple inflammatory diseases. In my view, GILD very astutely opens the pocketbook to gain access to this molecule once Abbvie (NYSE:ABBV) decided to pass on it in favor of their own in-house molecule as detailed in a previous post.
Source
Filgotinib continues to post excellent results for the treatment of Crohn's Disease as evidenced by the results of the FITZROY phase 2 study. The results shown above were determined based on endoscopic measures in addition to the CDAI index shown below. In essence, the endoscopic results offer visual confirmation in addition to the progress shown in the CDAI index, which in my view strengthens the case for Filgotinib. GILD/GLPG are advancing the molecule into Phase 3 trials for Crohn's Disease with an expected completion date of late 2019. Also, a data read for Ulcerative Colitis is due by year end. Filgotinib was also progressed into phase three for the very lucrative yet crowded Rheumatoid Arthritis market as well.